Brand Institute, a company involved in pharmaceutical and healthcare-related name development, announced on Friday that it has worked with United Kingdom-based Myovant Sciences for the development of the brand name ORGOVYX (relugolix), for an oral medication intended to treat adult patients with advanced hormone-sensitive prostate cancer.
Myovant Sciences developed the product, which it said is the first and only oral androgen deprivation therapy offered in Europe intended to treat advanced hormone-sensitive prostate cancer.
The European Commission (EC) has granted marketing authorisation for the product in all member states of the European Union, Iceland, Lichtenstein, and Norway. The product received US Food and Drug Administration (FDA) approval to treat adult patients with advanced prostate cancer in December 2020.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT